Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsPatient tumor organoids (PTO) were fabricated using unsorted tumor cells with and without enrichment with patient matched immune components derived from peripheral blood leukocytes, spleen, or lymph nodes.
[Clinical Cancer Research]
6445212 3U4EKY66 items 1 apa 0 default asc 1 164194 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-5b537d9b9f9d895ae83f5a55ead0687b%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%223U4EKY66%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Forsythe%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EForsythe%2C%20S.%20D.%2C%20Erali%2C%20R.%20A.%2C%20Sasikumar%2C%20S.%2C%20Laney%2C%20P.%2C%20Shelkey%2C%20E.%2C%20D%26%23x2019%3BAgostino%2C%20R.%2C%20Miller%2C%20L.%20D.%2C%20Shen%2C%20P.%2C%20Levine%2C%20E.%20A.%2C%20Soker%2C%20S.%2C%20%26amp%3B%20Votanopoulos%2C%20K.%20I.%20%282021%29.%20Organoid%20Platform%20in%20Preclinical%20Investigation%20of%20Personalized%20Immunotherapy%20Efficacy%20in%20Appendiceal%20Cancer%3A%20Feasibility%20Study.%20%3Ci%3EClinical%20Cancer%20Research%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-21-0982%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-21-0982%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3D3U4EKY66%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Organoid%20Platform%20in%20Preclinical%20Investigation%20of%20Personalized%20Immunotherapy%20Efficacy%20in%20Appendiceal%20Cancer%3A%20Feasibility%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20D.%22%2C%22lastName%22%3A%22Forsythe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%22%2C%22lastName%22%3A%22Erali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shyama%22%2C%22lastName%22%3A%22Sasikumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Preston%22%2C%22lastName%22%3A%22Laney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ethan%22%2C%22lastName%22%3A%22Shelkey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%22%2C%22lastName%22%3A%22D%27Agostino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lance%20D.%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perry%22%2C%22lastName%22%3A%22Shen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20A.%22%2C%22lastName%22%3A%22Levine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shay%22%2C%22lastName%22%3A%22Soker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Konstantinos%20I.%22%2C%22lastName%22%3A%22Votanopoulos%22%7D%5D%2C%22abstractNote%22%3A%22%3Cp%3EIntroduction%3A%20Immunotherapy%20efficacy%20data%20on%20appendiceal%20cancer%20%28AC%29%20from%20clinical%20trials%20does%20not%20exist%2C%20due%20to%20AC%20incidence%20of%200.97%20per%20100%2C000.%20The%20goal%20of%20this%20study%20was%20to%20preclinically%20explore%20the%20application%20of%20immunotherapy%20in%20treating%20AC%20in%20a%20personalized%20organoid%20model.%20Methods%3A%20Patient%20tumor%20organoids%20%28PTO%29%20were%20fabricated%20using%20unsorted%20tumor%20cells%20with%20and%20without%20enrichment%20with%20patient%20matched%20immune%20components%20derived%20from%20peripheral%20blood%20leukocytes%2C%20spleen%2C%20or%20lymph%20nodes%20%28iPTOs%29.%20Organoids%20were%20cultured%20for%207%20days%2C%20followed%20by%20treatment%20with%20immunotherapy%20%28Pembrolizumab%2C%20Ipilimumab%2C%20Nivolumab%29%2C%20and%20assessed%20for%20treatment%20efficacy.%20Results%3A%20Between%20September%202019%20and%20May%202021%2C%2026%20patients%20were%20enrolled%20in%20the%20study.%20Successful%20testing%20conducted%20in%2019%5C%2F26%20%2873.1%25%29%20patients%2C%20with%2013%5C%2F19%20%2868.4%25%29%20and%206%5C%2F19%20%2831.6%25%29%20patients%2C%20having%20low%20grade%20%28LGA%29%20and%20high%20grade%20appendiceal%20%28HGA%29%20primaries%2C%20respectively.%20Immunotherapy%20response%2C%20with%20increased%20expression%20of%20Granzyme%20B%20and%20Caspase%203%20and%20decreased%20expression%20of%20CK20%20and%20ATP%20activity%2C%20was%20exhibited%20in%204%5C%2F19%20%2821.1%25%29%20Pembrolizumab%20treated%20and%202%5C%2F19%20%2810.5%25%29%20Nivolumab%20treated%20iPTOs.%20Post%20immunotherapy%20cellular%20viability%2C%20in%20responding%20HGA%20organoids%20to%20Pembrolizumab%2C%20decreased%20to%20less%20than%2015%25%20%28p%20%26lt%3B%200.05%29.%20LGA%20iPTO%20treatment%20responses%20were%20observed%20in%20Pembrolizumab%20and%20Nivolumab%2C%20with%20an%208%25%20-%2047.4%25%20%28p%20%26lt%3B%200.05%29%20viability%20compared%20to%20controls.%20Ipilimumab%20showed%20no%20efficacy%20in%20the%20examined%20cohort.%20Conclusions%3A%20Immunotherapy%20shows%20measurable%20efficacy%20in%20AC%20organoids.%20Information%20derived%20from%20immunocompetent%20organoids%20may%20be%20applied%20in%20selecting%20patients%20for%20clinical%20trial%20enrollment%20in%20rare%20diseases%20where%20preclinical%20models%20of%20disease%20are%20lacking.%3C%5C%2Fp%3E%22%2C%22date%22%3A%222021%5C%2F01%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-21-0982%22%2C%22ISSN%22%3A%221078-0432%2C%201557-3265%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fclincancerres.aacrjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2021%5C%2F07%5C%2F01%5C%2F1078-0432.CCR-21-0982%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-07-02T16%3A48%3A50Z%22%7D%7D%5D%7D
Forsythe, S. D., Erali, R. A., Sasikumar, S., Laney, P., Shelkey, E., D’Agostino, R., Miller, L. D., Shen, P., Levine, E. A., Soker, S., & Votanopoulos, K. I. (2021). Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-21-0982 Cite
